The size of the global schizoaffective disorders treatment market is predicted to grow at a CAGR of 2.88% from 2024 to 2029 and is anticipated to be worth USD 8.77 billion by 2029 from USD 7.61 billion in 2024.
A schizoaffective disorder is a mental health disorder with symptoms such as mania, depression, and schizophrenia tendencies like hallucinations and delusional behavior. Schizoaffective disorder shares symptoms with schizophrenia and bipolar disorder, which can lead to misdiagnosis. According to the Diagnostic and statistical manual of mental Disorders (DMS – 5), 0.3% of the population suffers from a schizoaffective disease where a woman population is more than the men. The typical age for schizoaffective disorder is early adulthood, although it can occur anytime from adolescence through late life.
People with schizoaffective disorder generally respond to a combination of medications and psychotherapy, and this medicine to the patient depends on the symptoms of the disease. Other methods like psychotherapy, life skills training, hospitalization, and electroconvulsive therapy are for adults who do not respond to psychotherapy or medication. Only one drug that the US FDA approves and many more are in the pipeline stage, propelling the market growth. Ongoing research in the field of schizoaffective disorder is boosting market growth. In addition, the adoption of advanced technology is significantly influencing the market's demand.
For instance, schizoaffective disorder (1/2%) affects about one in every 200 persons at some point in their lives. One of the most prevalent major mental diseases, along with schizophrenia, is schizoaffective disorder. Furthermore, in the post-COVID era, there has been a rapid increase in mental disorders stats, leading to more revenue for the market. For example, according to WHO, in 2018, 970 million individuals worldwide, or 1 in every eight persons, had a mental illness, including anxiety and depressive disorders. Now, around 19.86% of adults are experiencing a mental illness worldwide. Therefore, there is a need for more awareness and care regarding mental health supporting the market expansion.
Stringent rules and regulations by the government regarding public safety are slowly declining the market's growth rate. In addition, the diagnosis of schizoaffective disorder is less reliable and is limiting the demand of the market.
REPORT METRIC |
DETAILS |
Market Size Available |
2023 to 2029 |
Base Year |
2023 |
Forecast Period |
2024 to 2029 |
Segments Covered |
By Treatment, Cause of Disorder, Type, and Region |
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter's Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
Regions Covered |
North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa |
Key Market Players |
Merz Pharma GmbH & Co. KGaA., Eli Lilly and Company, Elan Pharmaceuticals, Ciba Pharmaceuticals, Abbott Pharmaceuticals, AstraZeneca plc, and Janssen-Cilag Pty Limited. |
The antipsychotic segment is leading with the highest shares of the market. The growth is credited to advanced healthcare facilities and the availability of a well-structured regulatory framework.
The mood stabilizers and antidepressants segment is also expected to dominate the market revenue during the forecast period because common psychological treatments include a combination of these drugs to induce treatment in the patient. Due to multiple symptoms and the need to curb all the problems, these diseases are prescribed to critically ill schizoaffective patients.
The genetic factors segment is the leading segment of the treatment of schizoaffective disease over the analysis period. Factors like quick improvement in the healthcare industry and the growing healthcare industry propel the market's growth.
The environmental factors segment is also expected to show significant revenue during the forecast period due to the rising levels of stress and pressure among the younger generations and the extensive stereotypes of perfect success in society today.
The manic segment is considered to hold the largest market share of the schizoaffective disorders treatment market. The growth is due to advance technologies for medical tourism, fast access to the required procedures of the medical field, and lower cost for discretionary processes.
The depressive segment is also expected to show significant growth in the market due to rising cases of youth diagnosed with clinical depression and needing support and help from professionals. The mixed type also prevails as mental disorder diagnoses become more complex and integrated.
North America was the largest regional segment for schizoaffective disorders treatment globally in 2023, while Europe and the Asia Pacific regions followed. The dominance of North America and Europe is due to the advanced healthcare infrastructures, strict government rules regarding the production and supply of medications, and the increasing research and development in the field. Additionally, the presence of key market players in countries like the U.S., Canada, the U.K., France, Germany, Italy, etc., is expected to promote market growth in the region.
The Asia-Pacific region is expected to have the fastest growth rate during the forecast period, owing to increasing healthcare spending, rising disposable income, availability of advanced healthcare facilities, and rising awareness about available healthcare facilities. Additionally, the Asia-Pacific market is rising due to the growing preference toward medical tourism and first-class service in countries like China, India, Japan, South Korea, etc., for lower costs than developed regions.
Some of the major players in the global schizoaffective disorders treatment market profiled in this report are Merz Pharma GmbH & Co. KGaA., Eli Lilly and Company, Elan Pharmaceuticals, Ciba Pharmaceuticals, Abbott Pharmaceuticals, AstraZeneca plc, and Janssen-Cilag Pty Limited.
By Treatment
By Cause of Disorder
By Type
By Region
Frequently Asked Questions
The schizoaffective disorders treatment market in North America is expected to grow significantly and hold the largest share of the revenue during the forecast period.
Merz Pharma GmbH & Co. KGaA., Eli Lilly and Company, Elan Pharmaceuticals, and Ciba Pharmaceuticals are the several key market players schizoaffective disorders treatment market.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region